Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer

Cancer Research

Volumn 60, Issue 19, 2000, Pages 5522-5528

  Dannull, J ^a   Diener, P A ^a   Prikler, L ^a   Furstenberger, G ^a   Cerny, T ^a   Schmid, U ^a   Ackermann, D K ^a   Groettrup, M ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; PROSTATE STEM CELL ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE SPECIFICITY; TUMOR CELL;

ANTIGENS, NEOPLASM; CANCER VACCINES; EPITOPES, T-LYMPHOCYTE; GENE EXPRESSION; HLA-A ANTIGENS; HUMAN; IMMUNOTHERAPY, ACTIVE; MALE; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; ORGAN SPECIFICITY; PEPTIDE FRAGMENTS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0034306972     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Molecular and cellular biology of prostate cancer
2. Immunologic approaches to the treatment of prostate cancer
3. Follow-up evaluation of a Phase II prostate cancer vaccine trial
4. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
5. + cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide
6. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen
7. Purification of a human prostate specific antigen
8. Molecular cloning of complementary DNA encoding a prostate-specific membrane antigen
9. Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase
10. Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family
11. Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database
12. Isolation from human seminal plasma of an abundant 16-kDa protein originating from the prostate, its identification with a 94-residue peptide originally described as β-inhibin
13. STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors
14. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer
15. PART-I: A novel human prostate-specific, androgen-regulated gene that maps to chromosome 5q12
16. Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens
17. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
18. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
19. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
20. The response of poorly differentiated prostatic tumors to staining for prostate specific antigen and prostatic acid phosphatase: A comparative study
21. Prostate specific membrane antigen (PSM) is expressed in various human tissues: Implication for the use of PSM reverse transcription polymerase chain reaction to detect hematogenous prostate cancer spread
22. In situ hybridization study of PSP94 (prostatic secretory protein of 94 amino acids) expression in human prostates
23. Discovery of three genes specifically expressed in human prostate by expressed sequence tag database analysis
24. Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens
25. Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer
26. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer
27. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer
28. Genetic polymorphism within HLA-A·02: Significant allelic variation revealed in different populations
29. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer
30. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)
31. Characterization of the GAGE genes that are expressed in various human cancers and in normal testis
32. SYFPEITHI: Database for MHC ligands and peptide motifs
33. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains
34. Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA
35. Generation of an immunodominant CTL epitope is affected by proteasome subunit composition and stability of the antigenic protein
36. Peptide antigen production by the proteasome: Complexity provides efficiency
37. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells